LONDON/COPENHAGEN, Feb 5 (Reuters) - Novo Nordisk defended its next-generation obesity drug candidate CagriSema on Wednesday following late-stage trial data published in December that disappointed ...

LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid ...

Novo Nordisk is planning a new Phase III trial for CagriSema, the company’s next-generation obesity drug touted as a potential successor to Wegovy (semaglutide), as the company aims to quell ...

Only 57.3% of patients in the CagriSema trial reached the highest dose, with Novo providing no explanation for the low figure. A trial participant lost 18% of her weight but reported severe side ...

We’re beyond excited to share that the Vista Chamber of Commerce has been recognized by the Western Association of Chamber Executives (WACE) with not just one, but two prestigious awards!

LONDON/SAN FRANCISCO (Reuters) - Novo Nordisk (NVO) is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over ...

LONDON/SAN FRANCISCO (Reuters) – Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid a lack of clarity over trial ...

Novo Nordisk said it plans to file for the first regulatory approval for its weight-loss drug CagriSema during the first quarter of 2026. Novo Nordisk's (NVO) U.S.-listed shares rose 5% in ...

With its Q4 2024 results on Wednesday, Novo Nordisk (NVO) announced a new Phase 3 trial to test its highly-anticipated weight loss therapy, CagriSema, after a December readout failed to meet ...